Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Operating Leases (2019 - 2023)

Historic Operating Leases for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to $10.1 million.

  • ADC Therapeutics' Operating Leases rose 5215.95% to $10.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was $10.1 million, marking a year-over-year increase of 5215.95%. This contributed to the annual value of $6.6 million for FY2022, which is 9375187.3% up from last year.
  • ADC Therapeutics' Operating Leases amounted to $10.1 million in Q3 2023, which was up 5215.95% from $10.8 million recorded in Q2 2023.
  • ADC Therapeutics' Operating Leases' 5-year high stood at $11.0 million during Q1 2023, with a 5-year trough of $2605.0 in Q3 2020.
  • Its 5-year average for Operating Leases is $6.1 million, with a median of $6.6 million in 2022.
  • Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 27563896.35% in 2021, then tumbled by 2130.85% in 2022.
  • Quarter analysis of 5 years shows ADC Therapeutics' Operating Leases stood at $5.0 million in 2019, then crashed by 99.95% to $2605.0 in 2020, then surged by 168.48% to $6994.0 in 2021, then soared by 93751.87% to $6.6 million in 2022, then soared by 53.5% to $10.1 million in 2023.
  • Its last three reported values are $10.1 million in Q3 2023, $10.8 million for Q2 2023, and $11.0 million during Q1 2023.